🔍

ZYDUSWELL - Zydus Wellness

📊 NSE: ZYDUSWELL 🏢 Food - Processing - Indian 📅 Last Updated: 12/14/2025 15:25

📢 Recent Corporate Announcements

Zydus Wellness Designated Persons Acquire 2,037 Shares via Open Market

🟢 POSITIVE ⭐ 3/10

REGULATORY 📅 09 Mar 2026, 06:10 PM

Three designated persons of Zydus Wellness Limited—Vineet Shrivastava, Yatin Desai, and Rajat Bhargava—have purchased equity shares from the open market. The acquisitions occurred between March 2 and March 6, 2026, involving a total of 2,037 shares. The combined transaction value for these purchases is approximately ₹7.78 lakhs. While the volume is small relative to the company's total market capitalization, insider buying is typically interpreted as a sign of management's confidence in the company's future performance.

Vineet Shrivastava acquired 787 shares for ₹3,00,659.70 on March 2, 2026
Yatin Desai purchased 500 shares for ₹1,89,920 on March 4, 2026
Rajat Bhargava bought 750 shares for ₹2,87,355.85 on March 6, 2026
Total insider acquisition amounted to 2,037 shares valued at approximately ₹7.78 lakhs
All transactions were conducted through the open market on the National Stock Exchange (NSE)

💡 The transaction size is negligible compared to the company's market cap and should not be the sole basis for an investment decision. However, it serves as a minor positive indicator of internal sentiment among designated personnel.

Zydus Wellness Designated Person Punit Adhia Acquires 300 Shares via Open Market

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Mar 2026, 06:23 PM

Mr. Punit Adhia, a Designated Person at Zydus Wellness, purchased 300 equity shares from the open market on March 6, 2026. The total value of the acquisition was approximately ₹1.14 lakh. This transaction marks the individual's initial holding in the company, as they previously held zero shares. Given the very small volume of shares involved, this transaction is unlikely to impact the stock's market performance.

Designated Person Punit Adhia acquired 300 equity shares on March 6, 2026.
The total acquisition value was ₹1,14,300 via open market purchase.
Post-transaction holding increased from 0 to 300 shares (0.00% stake).
The disclosure was made under SEBI Prohibition of Insider Trading Regulations.

💡 This is a minor insider transaction with negligible impact on shareholding patterns. Investors should continue to monitor the company's quarterly earnings and growth outlook rather than this specific trade.

Zydus Wellness to Participate in Non-Deal Road Show in Singapore on March 18-19, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 06:20 PM

Zydus Wellness Limited has announced its participation in a Non-Deal Road Show scheduled for March 18 and 19, 2026, in Singapore. The event is organized by Motilal Oswal Capital Markets (Singapore) Pte, Ltd and will involve one-on-one and group meetings with institutional investors. This routine interaction is aimed at engaging with the global investment community to discuss the company's business environment and strategy. No unpublished price-sensitive information is expected to be shared during these meetings.

Participation in a Non-Deal Road Show in Singapore on March 18 and 19, 2026.
Meetings organized by Motilal Oswal Capital Markets (Singapore) Pte, Ltd.
Format includes both one-on-one and group interactions with institutional investors.
Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 This is a routine investor engagement activity; shareholders should monitor for any investor presentations or transcripts released following the event for strategic insights.

Zydus Wellness CFO Umesh V. Parikh Acquires 250 Shares via Open Market

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Mar 2026, 02:00 PM

Zydus Wellness CFO Umesh V. Parikh purchased 250 equity shares of the company from the open market on March 2, 2026. The transaction, valued at approximately Rs. 95,019, increased his total holding from 18,755 to 19,005 shares. Although the volume is small, such insider acquisitions are typically viewed as a positive signal of management's confidence. This disclosure is a standard regulatory filing under SEBI's Prohibition of Insider Trading regulations.

CFO Umesh V. Parikh acquired 250 equity shares on March 2, 2026
The total transaction value amounted to Rs. 95,019
Post-transaction holding increased to 19,005 shares from 18,755
The acquisition was executed through the open market on the BSE

💡 No immediate action is required as the transaction volume is negligible. Investors should continue to focus on the company's quarterly performance and broader market trends.

Zydus Wellness Designated Person Acquires 507 Shares via Open Market

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Mar 2026, 05:14 PM

Mr. Vineet Shrivastava, a Designated Person at Zydus Wellness Limited, acquired 507 equity shares of the company on February 26, 2026. The transaction was conducted through the open market on the National Stock Exchange for a total consideration of approximately Rs. 1.99 lakhs. Prior to this acquisition, the individual held no shares in the company. This disclosure is a routine filing under SEBI's Prohibition of Insider Trading regulations.

Designated Person Vineet Shrivastava purchased 507 equity shares on February 26, 2026
The total value of the open market acquisition was Rs. 1,99,504.50
Post-acquisition, the individual's holding increased from 0 to 507 shares
The transaction represents a negligible percentage (0.00%) of the company's total equity

💡 This is a minor insider purchase and does not warrant any immediate change in investment strategy. Investors should focus on upcoming quarterly results and broader consumer goods sector trends.

Zydus Wellness CEO Tarun Arora Acquires 4,000 Shares via Open Market

🟢 POSITIVE ⭐ 4/10

MANAGEMENT 📅 16 Feb 2026, 05:29 PM

Mr. Tarun Arora, the CEO and Whole Time Director of Zydus Wellness, has purchased 4,000 equity shares of the company from the open market. The transaction, valued at approximately Rs. 16.25 lakhs, was executed between February 12 and 13, 2026. Following this acquisition, his total shareholding has increased from 11,000 to 15,000 shares. Insider buying by a top executive is typically viewed as a positive signal of confidence in the company's future performance and valuation.

CEO Tarun Arora purchased 4,000 equity shares through the open market
The total transaction value is approximately Rs. 16,25,585
Individual shareholding of the CEO increased from 11,000 to 15,000 shares
The acquisition was completed on February 13, 2026, and disclosed under SEBI PIT Regulations

💡 Investors should view this insider purchase as a sign of management confidence, though the transaction size is relatively small compared to the company's total market capitalization. No immediate action is required, but it supports a positive long-term outlook.

Zydus Wellness Insider Acquisition: Spouse of Designated Person Buys 1,000 Shares

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 09:18 PM

Mrs. Nidhi Punit Adhia, the spouse of a Designated Person at Zydus Wellness, acquired 1,000 equity shares through the open market on February 6, 2026. The total value of the transaction was approximately ₹3.89 lakhs, executed on the National Stock Exchange. While the volume is negligible relative to the company's total equity, insider purchases are generally viewed as a sign of management's confidence in the business. This disclosure is a routine regulatory filing under SEBI's Prohibition of Insider Trading regulations.

Acquisition of 1,000 equity shares by the spouse of a Designated Person
Total transaction value amounted to ₹3,89,590
Trade executed via the open market on the NSE on February 6, 2026
Post-acquisition holding of the individual stands at 1,000 shares (0.00%)

💡 This is a minor insider transaction and does not necessitate any immediate change in investment stance. Investors should continue to monitor the company's fundamental performance and quarterly earnings reports.

Zydus Wellness Q3 FY26 Net Sales Surge 113.7% Driven by Comfort Click Acquisition

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 10:04 AM

Zydus Wellness reported a massive 113.7% YoY increase in net sales for Q3 FY26, primarily fueled by the integration of the Comfort Click acquisition. While the company reported a net loss of INR 399 million due to high amortization and interest costs from the acquisition, EBITDA grew by 312.2% to INR 610 million. Gross margins expanded significantly to 63% as the new business operates at higher margins, with management targeting 66-67% on an annualized basis. The RiteBite business also showed strong momentum, doubling its legacy performance and nearing double-digit EBITDA margins.

Net sales grew 113.7% YoY, with the Food & Nutrition segment surging 134%
EBITDA increased by 312.2% YoY to INR 610 million, with margins expanding to 6.3%
Gross margins reached 63% due to the high-margin Comfort Click portfolio mix
Reported a net loss of INR 399 million after accounting for INR 472 million in brand amortization and INR 371 million in interest
RiteBite Max Protein business doubled its legacy performance and is approaching double-digit margins

💡 Investors should focus on the strong operational growth and margin expansion post-acquisition, while monitoring the deleveraging process and the impact of non-cash amortization on reported profits.

Zydus Wellness Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 03 Feb 2026, 09:59 PM

Zydus Wellness has officially released the audio recording of its investor conference call held for the quarter and nine months ended December 31, 2025. This follows the company's announcement of its unaudited financial results for the same period. The recording provides management's detailed commentary on the company's operational performance and strategic outlook. Investors can access the full audio via the company's investor relations website to evaluate the business trajectory.

Audio recording for Q3 FY26 and nine-month period ended Dec 31, 2025, is now publicly available.
The disclosure is made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
The call covers the unaudited financial results for the period ending December 2025.
Direct access link provided: https://zyduswellness.com/investor/Investor-Concall-recording-Q3-FY-26.mp3.

💡 Investors should listen to the recording to gain insights into management's views on raw material costs and demand trends in the consumer wellness segment. This is a routine update and does not contain new financial data beyond what was already reported in the results.

Zydus Wellness Q3 FY26 Net Sales Surge 113.7% to Rs 9,633 Mn; EBITDA Jumps 312%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 12:57 PM

Zydus Wellness reported a massive 113.7% year-on-year growth in net sales for Q3 FY26, reaching Rs 9,633 million, largely driven by the integration of newly acquired businesses. EBITDA saw an even more significant jump of 312.2% to Rs 610 million, reflecting improved operational efficiency and margin expansion in brands like RiteBite. The company maintained dominant market leadership in key categories, including Sugar Free with a 96.3% share and Glucon-D with a 59% share. Furthermore, the expansion of the 'WeightWorld' brand into European markets like Poland and Finland signals a strong international growth strategy.

Net Sales grew by 113.7% y-o-y to Rs 9,633 million, while EBITDA rose 312.2% to Rs 610 million.
Sugar Free maintained a dominant 96.3% market share, gaining 80 basis points year-on-year.
RiteBite Max Protein margins improved from breakeven a year ago to near double-digit levels.
Glucon-D and Nycil retained leadership positions with 59% and 33.1% market shares respectively.
International expansion continued with Comfort Click entering Poland, Finland, and Portugal.

💡 Investors should view the strong sales and EBITDA growth as a sign of successful acquisition integration and brand strength. Monitor the sustainability of margins in the newly acquired segments and the performance of international expansions.

Zydus Wellness Q3 FY26 Net Sales Surge 113.7% to ₹963 Cr; Gross Margins Expand 1561 bps

🔵 WATCH ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 12:53 PM

Zydus Wellness reported a massive 113.7% YoY increase in net sales to ₹963.3 crore for Q3 FY26, primarily driven by the integration of Comfort Click and strong momentum in the RiteBite Max Protein business. Gross margins saw a significant expansion of 1561 bps to 63.3%, aided by a favorable product mix and newly acquired international brands. Despite the top-line surge, the company reported a PAT loss of ₹39.9 crore for the quarter, compared to a profit of ₹6.4 crore in the previous year, reflecting acquisition-related impacts. Core brands like Sugar Free and Everyuth maintained dominant market leadership with 96.3% and 48.5% shares respectively.

Net Sales for Q3 FY26 grew by 113.7% YoY to ₹9,633 million, while YTD FY26 sales rose 38.4% to ₹24,639 million.
Gross Margin expanded significantly by 1561 bps YoY to 63.3% in Q3 FY26, driven by premiumization and the Alidac UK acquisition.
RiteBite Max Protein business doubled its legacy performance and achieved nearing double-digit EBITDA margins post-integration.
Sugar Free maintains a dominant 96.3% market share, while Everyuth Scrub holds 48.5% of its category.
International business expanded into Poland, Finland, and Portugal through the WeightWorld brand under Comfort Click.

💡 Investors should monitor the company's ability to translate high top-line growth and expanded gross margins into bottom-line profitability as acquisition costs stabilize. The strong market share in core categories provides a defensive moat, but the impact of seasonal brands like Glucon-D and Nycil remains a key variable for upcoming quarters.

Zydus Wellness Q3 Standalone Revenue Jumps 53% to ₹1,526 Million; Net Profit at ₹121 Million

🔵 WATCH ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 12:44 PM

Zydus Wellness reported a robust 53% year-on-year growth in standalone revenue for Q3 FY26, reaching ₹1,526 million. However, standalone net profit remained nearly flat at ₹121 million compared to ₹118 million in the previous year, primarily due to higher material costs and exceptional items. The company recognized a ₹15 million one-time charge related to the New Labour Codes and completed the consolidation of Naturell (India) Private Limited. Investors should note a significant net loss of ₹1,062 million reported by a key subsidiary in the consolidated results, which may weigh on overall group performance.

Standalone Revenue from operations increased 53% YoY to ₹1,526 million from ₹997 million.
Standalone Net Profit stood at ₹121 million, showing a marginal 2.5% growth YoY.
Exceptional items include ₹15 million for New Labour Code compliance and ₹97 million related to Naturell India liquidation.
A major subsidiary reported a significant net loss of ₹1,062 million for the quarter ended December 31, 2025.
Equity shares were successfully sub-divided from a face value of ₹10 to ₹2 effective September 19, 2025.

💡 While standalone revenue growth is impressive, investors should exercise caution due to the substantial losses reported in the consolidated subsidiary. Monitor the management's commentary on the turnaround of subsidiary operations and the margin pressure from rising material costs.

Zydus Wellness to Host Q3FY26 Earnings Call on February 3, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jan 2026, 05:49 PM

Zydus Wellness Limited has scheduled a teleconference call for analysts and institutional investors on February 3, 2026, at 4:00 p.m. IST. The call is intended to discuss the company's unaudited financial results for the third quarter and nine-month period ending December 31, 2025. Senior management, including the Chairman, CEO, and CFO, will be present to provide insights and answer queries. Investors can join using the universal access numbers +91 22 6280 1144 or +91 22 7115 8045.

Conference call scheduled for February 3, 2026, at 16:00 hrs India Time.
Focus on unaudited financial results for Q3 and the nine months ended December 31, 2025.
Top management including Chairman Dr. Sharvil Patel and CEO Tarun Arora will represent the company.
International toll-free access provided for USA, UK, Hong Kong, and Singapore investors.

💡 Investors should monitor the Q3 results release on the same day and attend the call to understand management's guidance on margin pressures and demand trends in the wellness segment.

Zydus Wellness Gets Interim Relief from Gujarat HC on ₹56.33 Crore GST Demand

🟢 POSITIVE ⭐ 6/10

LEGAL 📅 10 Jan 2026, 11:37 AM

Zydus Wellness's subsidiary, ZWPL, has secured ad-interim relief from the Gujarat High Court regarding a GST demand of ₹56.33 crores plus interest and penalties. The court has restrained further proceedings related to the Order-in-Original dated September 30, 2025. Crucially, the company stated that the tax liability pertains to the period before January 30, 2019, which is prior to the acquisition. This liability is fully indemnified by Heinz Italia S.P.A., meaning there is no direct financial impact on Zydus Wellness.

Gujarat High Court granted ad-interim relief restraining proceedings for a ₹56.33 crore GST demand.
The demand was issued by the DGGI, Surat Zonal Unit, under Section 74(5) of the CGST Act.
The tax dispute relates to the pre-acquisition period prior to January 30, 2019.
Liability is fully indemnified by Heinz Italia S.P.A., protecting the company's balance sheet.
The writ petition was filed under Article 226 of the Constitution of India challenging the OIO.

💡 Investors should take comfort in the fact that the liability is indemnified by the previous owner, Heinz, and the court has stayed the proceedings. No immediate negative impact on the company's financials is expected.

Zydus Wellness Files Quarterly SEBI Compliance Certificate for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 06:33 PM

Zydus Wellness Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The filing confirms that equity share certificates received for dematerialization were duly verified, mutilated, and cancelled by the Registrar and Share Transfer Agent (RTA). The company's RTA, MUFG Intime India Private Limited, has ensured that the names of the depositories were substituted as registered owners in the records. This is a standard procedural disclosure required by SEBI to maintain the integrity of shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Confirmation of adherence to SEBI Regulation 74(5) regarding dematerialization of shares.
RTA MUFG Intime India Private Limited verified and cancelled physical certificates after processing.
Updated depository names in the register of members within prescribed SEBI timelines.

💡 No action is required from investors as this is a routine administrative filing confirming regulatory compliance.

View All ZYDUSWELL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue reached INR 1,766.8 Cr in FY20, a 109.7% increase from INR 842.3 Cr in FY19, reflecting the first full year of the Heinz acquisition. Revenue is expected to marginally de-grow in FY21 due to COVID-19 lockdowns but grow by 10-12% over the medium term. E-commerce channels for Complan are seeing growth rates of 15-20%.

Geographic Revenue Split

The company is expanding its international footprint, specifically building presence in Europe and the U.S. through the Comfort Click acquisition. Domestic revenue is heavily concentrated in India, with a direct reach of 6.2 lakh outlets and a total availability of 2.9 million outlets.

Profitability Margins

Operating margins stood at 18.2% in FY20, down from 20.7% in FY19 due to higher agro-commodity prices and one-time acquisition costs. Adjusted PAT margin was -17.1% in FY20 (INR -302 Cr) after accounting for brand/goodwill amortization over 10 years, compared to 11.8% (INR 99 Cr) in FY19.

EBITDA Margin

Operating margin is expected to sustain at 18-19% over the medium term. EBITDA interest coverage was 2.33 times in FY20, down from 6.47 times in FY19. Debt to EBITDA is projected to improve to less than 2 times in FY21 from 4.7 times in FY20.

Capital Expenditure

The company undertook a massive acquisition of Heinz for INR 4,700 Cr. Recent equity infusions of INR 1,000 Cr (INR 350 Cr from Zydus Family Trust and INR 650 Cr via QIP) are being utilized for debt reduction.

Credit Rating & Borrowing

CRISIL AA+/Stable (Reaffirmed as of October 2020). Borrowing costs are being optimized by refinancing INR 500 Cr of NCDs and reducing total debt by INR 1,000 Cr to improve gearing to 0.14x.

⚙️ Operational Drivers

Raw Materials

Agro-commodities including milk, sugar, and other food ingredients represent the primary cost base. Specific percentage of total cost for each is not disclosed, but price hikes in these commodities reduced margins by approximately 250 basis points in FY20.

Import Sources

Primarily sourced from domestic Indian markets for legacy brands; international sourcing for Comfort Click operations in Europe.

Capacity Expansion

Focus is on distribution expansion rather than just manufacturing capacity; aiming to increase direct reach from 6.2 lakh outlets to 3.5 million outlets in the coming quarters.

Raw Material Costs

Raw material costs are subject to agro-commodity price volatility. The company uses its scale post-Heinz acquisition to drive procurement synergies with the Zydus Cadila group.

Manufacturing Efficiency

Synergies with Zydus Cadila pharma distribution channels are expected to improve blended operating efficiency.

Logistics & Distribution

Direct distribution reach of 6.2 lakh outlets; total availability across 2.9 million outlets. Distribution is a key growth lever for the RiteBite and legacy portfolios.

📈 Strategic Growth

Expected Growth Rate

10-12%

Growth Strategy

Growth will be driven by integrating the distribution of acquired brands (Heinz, RiteBite, Comfort Click), expanding direct reach to 3.5 million outlets, and launching new product variants. The company is also leveraging e-commerce (15-20% growth in Complan) and international expansion into the US and Europe.

Products & Services

Health food drinks, energy drinks, skin care powders, sugar substitutes, spreads, and protein bars.

Brand Portfolio

Sugar Free, Everyuth, Nutralite, Glucon D, Complan, Nycil, Sampriti Ghee, RiteBite Max Protein, WeightWorld, maxmedix, animigo.

New Products/Services

Expansion of the RiteBite Max Protein range and off-season variants for seasonal brands to balance the 70:30 revenue skew.

Market Expansion

Targeting 3.5 million total outlets in India and expanding the Comfort Click model in Europe and the U.S.

Market Share & Ranking

Complan market share is being 'protected' in key segments by focusing on larger, more profitable packs rather than value-eroding sachets.

Strategic Alliances

Strategic importance to parent Cadila Healthcare Ltd, which provides need-based financial support and management control.

🌍 External Factors

Industry Trends

Shift toward 'Low Sugar/No Sugar', 'High Protein', and 'Active Lifestyle' products. The industry is evolving toward functional wellness, and ZWL is positioning itself with brands like Sugar Free and RiteBite.

Competitive Landscape

Intense competition in the HFD (Health Food Drink) category from 2-3 major players, restricting pricing power and market share growth for Complan.

Competitive Moat

Strong brand equity in niche categories (Sugar Free, Glucon D) and a massive distribution network of 2.9 million outlets. Sustainability is backed by the Zydus Cadila group's pharma distribution synergy.